This week's roundup of Houston innovators includes Philip Dutton of Solidatus, Benjamin Foster of Nurseify, and Tasos Katsaounis of Bread Man Baking Co. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from baking to software development — recently making headlines in Houston innovation.


Philip Dutton, CEO of Solidatus

Philip Dutton is the new Houston-based CEO of Solidatus, a London-founded data management startup. Photo via LinkedIn

As part of a company reorganization, data management startup Solidatus has established Houston as its North American headquarters and has named co-founder Philip Dutton as its Houston-based CEO.

Founded in London in 2017, Solidatus initially focused on supplying data management software to businesses in Europe, the Middle East, and Africa, but has since extended its reach to North America. Overall, Solidatus employs more than 110 people. It plans to triple its U.S. headcount over the next year.

“Solidatus serves visionary organizations that desire streamlined access and clarity of their data to build smarter and more profitable businesses. That’s everyone from Fortune 500 companies that have an unmanageably complex data landscape to startups and scale-ups that want to optimize their data practices from the get-go. There is no greater concentration of these organizations than in the U.S.,” Dutton, who had been the co-CEO, says in a news release. Click here to read more.

Benjamin Foster, founder and CEO of Nurseify

Benjamin Foster was leading human resources at Gulf Coast Division during Hurricane Harvey when he saw a huge need for an alternative to hiring short-term nurses quickly. That's when he had the idea for Nurseify, a platform that allows for nurses to find jobs — and for facilities to find nurses with the specialties they need. The platform is now live in five pilot states — Texas, Georgia, Florida, South Carolina, and Nevada.

Nurses are facing a significant amount of burnout — in part due to what they went through during the pandemic, but also because of the stressful work environments due to hiring misalignment. Foster says he's intentionally designed the platform to be supportive of nurses.

"We want Nurseify to be known as the most nurse-friendly company in the world. We believe we can bridge the gap between administration and operations and nurses," Foster says. "We want 'Nurseify' to become a verb at some point." Click here to read more.

Tasos Katsaounis, CEO and founder of Bread Man Baking Co.

How Tasos Katsaounis took his hobby and let it rise into a booming Houston business. Image via breadmanco.com

Four years ago, while looking to escape the daily rigors of his corporate work stress, Houstonian Tasos Katsaounis began to bake bread between Zoom calls. He took that hobby and turned it into Bread Man Baking Co. – a Houston-based artisan bread business that can now be tasted in restaurants all throughout the city.

“You know, there’s just something about the idea of growing something from nothing,” Katsaounis, CEO and founder of the company, tells InnovationMap. “I really feel like for the first time in my 26 years of working professionally, that I'm doing what I'm supposed to be doing and I'm super passionate about what I do every day.”

At the end of 2021, the company expanded from its 5,000-square-foot kitchen and moved its operations into a new 40,000-square-foot facility on the northeast side of Houston, close to the Budweiser and Kroger distribution buildings. At the time of the move, it had 17 employees and this year it has since grown to 42. Click here to read more.

Philip Dutton is the new Houston-based CEO of Solidatus, a London-founded data management startup. Photo via LinkedIn

London-based data management tech firm announces new Houston HQ, CEO

new to hou

As part of a company reorganization, data management startup Solidatus has established Houston as its North American headquarters and has named co-founder Philip Dutton as its Houston-based CEO.

Founded in London in 2017, Solidatus initially focused on supplying data management software to businesses in Europe, the Middle East, and Africa, but has since extended its reach to North America. Overall, Solidatus employs more than 110 people. It plans to triple its U.S. headcount over the next year.

“Solidatus serves visionary organizations that desire streamlined access and clarity of their data to build smarter and more profitable businesses. That’s everyone from Fortune 500 companies that have an unmanageably complex data landscape to startups and scale-ups that want to optimize their data practices from the get-go. There is no greater concentration of these organizations than in the U.S.,” Dutton, who had been the co-CEO, says in a news release.

Dutton had shared co-CEO duties with the other co-founder, Philip Miller. Miller now holds the newly created role of chief innovation officer.

“We are extremely pleased that Solidatus chose Houston as their North American headquarters," says Susan Davenport, chief economic development officer of the Greater Houston Partnership. "Solidatus’ announcement solidifies the region’s position as a top U.S. metro for business relocations and expansions due to its global connectivity and access to a well-developed suite of key global industries, including energy, life sciences, and aerospace.”

Sheldon Feinland, the company’s newly installed New York City-based vice president of global sales, says year-over-year growth of 300 percent in North America is “well within our grasp.” The startup’s customers are in the financial services, health care, insurance, retail, manufacturing, and government sectors.

“We’re focused on creating unique solutions that untangle the messy world of data,” Feinland says. “This way, data becomes easier to work with, and we can maximize the potential of the organizations that house it.”

In 2021, Solidatus raised $19.2 million in a Series A funding round led by AlbionVC with participation from two customers, Citi and HSBC. Much of that money is being spent on the company’s North American expansion.

“We are at a point in the company’s progress and diversification across industries when new ideas are at an all-time premium. Now is absolutely the best time to take on this important new role,” Miller says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”